Medexus Pharmaceuticals Inc (MDP.TO) is facing a notable decline, with shares dropping 2.48% in the last trading session.
In a challenging trading day for Medexus Pharmaceuticals Inc, the stock closed at CA$3.94, reflecting a 2.48% decrease. This decline comes amidst a backdrop of market volatility and investor caution, particularly in the biotech sector.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$160.20M
52W high
$5.25
52W low
$2.47
1W change
+2.05%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 36.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+36.7% Upside
Current Price
C$4.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
49.8%
Annualized
90-Day Vol
42.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.29 | C$4.45 – C$6.28 |
| 60 trading days | C$5.61 | C$4.40 – C$7.15 |
| 90 trading days | C$5.95 | C$4.42 – C$8.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be aware of the potential risks associated with Medexus, especially given its recent performance and lack of significant news to drive positive sentiment.
Medexus Pharmaceuticals Inc down 2.48% today
With a market cap of CA$133.4 million, the company's financial health remains a concern as it navigates a competitive landscape.
Bull case
Despite the current downturn, Medexus has shown promise with its product GRAFAPEX. If market conditions improve, this could lead to future revenue growth.
Bear case
The recent drop in share price might signal deeper issues within the company or the sector. This is especially concerning given its negative profit margin and the lack of recent positive news.
Market Reaction to Medexus Pharmaceuticals
Advertisement
The recent drop in Medexus's stock price reflects a mix of market sentiment and the absence of significant news that could boost investor confidence. The biotech sector has faced scrutiny, and Medexus's performance mirrors broader trends affecting similar companies.
Financial Overview
With a market capitalization of CA$133.4 million and a profit margin around -0.27%, Medexus Pharmaceuticals is in a precarious position. Investors should consider these financial metrics when evaluating the stock's future potential. For more detailed insights, visit our MDP.TO stock page.
Looking Ahead
As Medexus navigates its current challenges, investors will be watching closely for updates on product developments or strategic initiatives. The company's ability to rebound will depend on external market conditions and internal performance metrics. For ongoing updates, check back on our MDP.TO stock page.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
